Our commitment to the global sustainable development agenda is at the core of our mission: transforming the lives of people living with rare and debilitating diseases. Our sustainability strategy is integrated into our business and focuses on two main priorities: maintaining our commitment to patients and always acting responsibly. By expanding our geographical reach, investing in the development of innovative medicines, and deepening our engagement in haematology, immunology, and specialty care, we are enhancing access to rare disease treatments for patients around the world, step by step. Learn more about our commitments to patients. https://lnkd.in/e6cSjDP4 #Sobi #RareDiseases #Sustainability
Sobi - Swedish Orphan Biovitrum AB (publ)’s Post
More Relevant Posts
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
-
Senior Talent Acquisition Leader | Full life-cycle recruiting | Sourcing techniques & tools | Inclusion recruiting | Campus recruiting | Recruitment planning | Candidate experience | Interview training | Team leadership
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
-
Company Group Chairman - Johnson & Johnson Innovative Medicine (EMEA) and Managing Director - J&J Innovative Medicine Campus Belgium
Over the past two decades, our commitment to redefining the standard of care has led us to the forefront of innovative treatments for autoimmune and inflammatory diseases. There are up to 70 million people in Europe living with Immune-Mediated Inflammatory Diseases (IMIDs) such as Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis and rheumatoid arthritis. To learn more about the world of IMIDs, listen to the first part of my discussion with Maria Raad, our Vice President, EMEA Commercial Strategy Lead, Immunology & Retina, and Ludovic de Beaucoudrey, Senior Director, Therapeutic Area Lead, Immunology & Retina. They walk me through the impact these diseases have on patients, the unmet needs, and our strides forward in this field at Johnson & Johnson. #Immunology #HealthcareInnovation #MyCompany #IMIDs
-
From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie
Immunology’s Next Frontier
abbvie.com
Executive Director, Program Delivery, Rare Disease & Pediatrics chez Premier Research
3moLove this